ES2139624T3 - Metabolitos hidroxilados y derivados de doxazosin como agentes anti-ateroesclerosis. - Google Patents

Metabolitos hidroxilados y derivados de doxazosin como agentes anti-ateroesclerosis.

Info

Publication number
ES2139624T3
ES2139624T3 ES93301505T ES93301505T ES2139624T3 ES 2139624 T3 ES2139624 T3 ES 2139624T3 ES 93301505 T ES93301505 T ES 93301505T ES 93301505 T ES93301505 T ES 93301505T ES 2139624 T3 ES2139624 T3 ES 2139624T3
Authority
ES
Spain
Prior art keywords
doxazosin
derivatives
hydroxylated metabolites
atherosclerosis
atherosclerosis agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93301505T
Other languages
English (en)
Inventor
Samuel Siu-Ming Wong
Archie Calhoun Swindell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2139624T3 publication Critical patent/ES2139624T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
    • H01L2924/15—Details of package parts other than the semiconductor or other solid state devices to be connected
    • H01L2924/181—Encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE AL USO DE CIERTOS METABOLITOS HIDROXILADOS Y DERIVADOS DE DOXAZOSINA Y SUS SALES DE ADICION DEL ACIDO ACEPTABLES FARMACEUTICAMENTE PARA RETARDAR EL DESARROLLO DE ATEROESCLEROSIS EN UN MAMIFERO. TALES COMPUESTOS SON UTILES PARA REDUCIR LA IMPLICACION DE LA PLACA ATEROESCLEROTICA Y PARA RETARDAR Y REDUCIR LA DEPOSICION DE LIPIDOS Y LA FIBROSIS EN EL DESARROLLO DE PLACAS ATEROESCLEROTICAS.
ES93301505T 1992-04-01 1993-02-26 Metabolitos hidroxilados y derivados de doxazosin como agentes anti-ateroesclerosis. Expired - Lifetime ES2139624T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86171492A 1992-04-01 1992-04-01

Publications (1)

Publication Number Publication Date
ES2139624T3 true ES2139624T3 (es) 2000-02-16

Family

ID=25336560

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93301505T Expired - Lifetime ES2139624T3 (es) 1992-04-01 1993-02-26 Metabolitos hidroxilados y derivados de doxazosin como agentes anti-ateroesclerosis.

Country Status (17)

Country Link
US (1) US5543411A (es)
EP (1) EP0564093B1 (es)
JP (1) JPH0624989A (es)
KR (1) KR0137927B1 (es)
AT (1) ATE187069T1 (es)
AU (1) AU660359B2 (es)
CA (1) CA2092983C (es)
DE (1) DE69327128T2 (es)
DK (1) DK0564093T3 (es)
ES (1) ES2139624T3 (es)
GR (1) GR3032373T3 (es)
HU (1) HU225113B1 (es)
IL (1) IL105141A (es)
MX (1) MX9301824A (es)
NZ (1) NZ247307A (es)
PT (1) PT564093E (es)
ZA (1) ZA932307B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120302A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
IL120303A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
WO2002024114A2 (en) * 2000-09-25 2002-03-28 Cohesion Technologies, Inc. Resorbable anastomosis stents and plugs
US20050165428A1 (en) * 2000-09-25 2005-07-28 Franco Kenneth L. Absorable surgical structure
KR101119387B1 (ko) 2003-07-18 2012-03-07 하마마츠 포토닉스 가부시키가이샤 절단방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB271997A (en) * 1926-04-16 1927-06-09 Morris Engines Coventry Ltd Improvements relating to the driving of cam or other auxiliary shafts in internal combustion engines
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
US4758569A (en) * 1987-08-26 1988-07-19 Pfizer Inc. Doxazosin as an anti-atherosclerosis agent

Also Published As

Publication number Publication date
DK0564093T3 (da) 2000-03-27
HU225113B1 (en) 2006-06-28
IL105141A0 (en) 1993-07-08
AU3562993A (en) 1993-10-07
MX9301824A (es) 1994-02-28
ATE187069T1 (de) 1999-12-15
JPH0624989A (ja) 1994-02-01
KR930021203A (ko) 1993-11-22
HU9300947D0 (en) 1993-06-28
US5543411A (en) 1996-08-06
DE69327128D1 (de) 2000-01-05
HUT65849A (en) 1994-07-28
GR3032373T3 (en) 2000-04-27
CA2092983A1 (en) 1993-10-02
AU660359B2 (en) 1995-06-22
CA2092983C (en) 1996-12-31
NZ247307A (en) 1997-06-24
PT564093E (pt) 2000-04-28
ZA932307B (en) 1994-09-30
EP0564093A1 (en) 1993-10-06
IL105141A (en) 1998-10-30
DE69327128T2 (de) 2000-04-20
EP0564093B1 (en) 1999-12-01
KR0137927B1 (ko) 1998-05-15

Similar Documents

Publication Publication Date Title
NO914091D0 (no) Fremgangsmaate for fremstilling av hydroksylerte inhibitorer for hiv-reverstranskriptase
FI932937A (fi) Anordning och daertill hoerande foerfarande foer kompensering av vridmomentets rippel i en permamagnet-elmotor
FI934361A0 (fi) Foerfarande och anordning foer evaluering av vaegningsparametrarna foer ensignal i en mottagare
FI961739A0 (fi) Amiinisuoloja klavulaanihapon valmistamiseksi
IL86735A0 (en) Doxazosin as an anti-atherosclerosis agent
FI951009A (fi) Muskariinin vastaisina aineina käyttökelpoisia diaryylipiperatsinoasetamidiyhdisteitä
MX9302116A (es) Compuestos azabiciclo.
EE02979B1 (et) Formoterool ja tema ühendid ning nende valmistamise meetod
ES2139624T3 (es) Metabolitos hidroxilados y derivados de doxazosin como agentes anti-ateroesclerosis.
EP0458160A3 (en) Substituted diphenylmethane derivatives as analgesic or anti-inflammatory agents
FI922777A0 (fi) Laitteisto telaston telavälysten säätämiseksi
NZ238124A (en) Heterocyclylalkylphosphonic acid and ester derivatives and pharmacueitcal compositions
DK0775692T3 (da) Guanidinomethylcyclohexancarboxylsyreesterderivater
ES2080445T3 (es) Derivados de ursano, su preparacion y formulaciones farmaceuticas de los mismos.
FR2649929B1 (fr) Poutre en caisson creuse en granite
FI914874A (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten C-3-ditioasetaalisubstituoitujen karbapeneemiyhdisteiden valmistamiseksi
DK30284A (da) Pyrrolidiner
ITRM920039V0 (it) Perfezionamenti alle maschere per la realizzazione di cartamodelli
BR7500931U (pt) Disposição construtiva proporcionada a obra de arte
UA286S (uk) Набір меблів для відпочинку
UA282S (uk) Набір мебелі для відпочинку
UA287S (uk) Набір меблів для відпочинку
KR940009705U (ko) 화구 박스용 테두리골재
BR7000839U (pt) Disposicao construtiva aplicada a equipamento destinado a reproducao imagens

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 564093

Country of ref document: ES